康宁杰瑞制药-B（股票代码：09966）今日盘中大涨5.03%，引发市场关注。这一显著涨幅主要得益于公司发布的强劲中期业绩报告。
根据康宁杰瑞制药-B公布的截至2025年6月30日的中期业绩，公司成功实现扭亏为盈。报告显示，公司在本期内实现营业额3.19亿元人民币，同比大幅增长84%。更值得注意的是，公司净利润达到2,157.5万元人民币，相比去年同期4,489.6万元的亏损，实现了显著的业绩改善。每股盈利为0.02元人民币。
这一亮眼的业绩表现无疑增强了投资者对康宁杰瑞制药-B未来发展的信心。尽管公司宣布不派息，但其营收的大幅增长和成功扭亏为盈的事实，仍然引发了市场的积极反应，推动了股价的上涨。作为一家生物制药公司，康宁杰瑞制药-B的这一业绩改善可能预示着其研发投入开始获得回报，或核心业务正在步入快速增长轨道。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.